ChemoCentryx, Inc.
CCXI
CCXI was delisted on the 19th of October, 2022.
217 hedge funds and large institutions have $3.2B invested in ChemoCentryx, Inc. in 2022 Q3 according to their latest regulatory filings, with 84 funds opening new positions, 55 increasing their positions, 57 reducing their positions, and 48 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 3 → 12 (+9)
122% more capital invested
Capital invested by funds: $1.44B → $3.2B (+$1.76B)
75% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 48
63% more call options, than puts
Call options by funds: $40.3M | Put options by funds: $24.8M
19% more funds holding
Funds holding: 182 → 217 (+35)
4% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$212M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$113M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$74.4M |
| 4 |
SFM
Soros Fund Management
New York
|
+$65.1M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$59.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$441M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$97.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$55M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$52.1M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$47.5M |
CCXI Hedge Fund Activity: Q3 2022 in Review
217 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q3 2022, worth a combined $3.2B — up 122% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new CCXI positions and 48 closed out — a net gain of 36 holders — while 55 added to existing stakes and 57 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $212M. The largest seller was Fidelity Investments, cutting an estimated $441M.
- 217 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q3 2022, up from 182 in Q2 2022.
- Funds reported $3.2B of ChemoCentryx, Inc. stock for Q3 2022, up 122% quarter-over-quarter.
- 84 funds opened new ChemoCentryx, Inc. positions in Q3 2022 and 48 closed out, a net change of +36 holders.
- The largest ChemoCentryx, Inc. buyer in Q3 2022 was Goldman Sachs, an estimated $212M added.
- The largest ChemoCentryx, Inc. seller in Q3 2022 was Fidelity Investments, an estimated $441M sold.
Based on aggregated 13F filings for Q3 2022.